Crispr Theraptc (NASDAQ:CRSP) Director Kurt Von Emster sold 55,569 shares of the business’s stock in a transaction dated Tuesday, August 15th. The shares were sold at an average price of $19.59, for a total value of $1,088,596.71. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
Kurt Von Emster also recently made the following trade(s):
- On Tuesday, August 8th, Kurt Von Emster sold 35,473 shares of Crispr Theraptc stock. The shares were sold at an average price of $18.63, for a total value of $660,861.99.
- On Friday, August 4th, Kurt Von Emster sold 50,477 shares of Crispr Theraptc stock. The shares were sold at an average price of $17.81, for a total value of $898,995.37.
- On Tuesday, August 1st, Kurt Von Emster sold 5,512 shares of Crispr Theraptc stock. The shares were sold at an average price of $17.51, for a total value of $96,515.12.
- On Friday, July 28th, Kurt Von Emster sold 41,312 shares of Crispr Theraptc stock. The shares were sold at an average price of $17.63, for a total value of $728,330.56.
- On Wednesday, July 26th, Kurt Von Emster sold 32,930 shares of Crispr Theraptc stock. The shares were sold at an average price of $17.60, for a total value of $579,568.00.
- On Friday, July 14th, Kurt Von Emster sold 69,859 shares of Crispr Theraptc stock. The shares were sold at an average price of $16.84, for a total value of $1,176,425.56.
- On Wednesday, July 12th, Kurt Von Emster sold 31,992 shares of Crispr Theraptc stock. The shares were sold at an average price of $16.56, for a total value of $529,787.52.
- On Wednesday, July 5th, Kurt Von Emster sold 4,254 shares of Crispr Theraptc stock. The shares were sold at an average price of $16.26, for a total value of $69,170.04.
- On Thursday, June 29th, Kurt Von Emster sold 43,202 shares of Crispr Theraptc stock. The shares were sold at an average price of $16.90, for a total value of $730,113.80.
- On Tuesday, June 27th, Kurt Von Emster sold 81,435 shares of Crispr Theraptc stock. The shares were sold at an average price of $17.08, for a total value of $1,390,909.80.
Crispr Theraptc (NASDAQ CRSP) traded down 2.33% on Thursday, reaching $18.42. The company’s stock had a trading volume of 156,193 shares. The company’s market capitalization is $747.69 million. Crispr Theraptc has a 12-month low of $11.63 and a 12-month high of $25.00. The firm has a 50-day moving average of $17.28 and a 200 day moving average of $17.50.
Crispr Theraptc (NASDAQ:CRSP) last issued its quarterly earnings data on Thursday, August 10th. The company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($0.62) by $0.06. Crispr Theraptc had a negative return on equity of 47.46% and a negative net margin of 406.61%. The company had revenue of $3.60 million for the quarter, compared to analyst estimates of $3.29 million. Crispr Theraptc’s revenue was up 350.0% on a year-over-year basis. On average, equities research analysts anticipate that Crispr Theraptc will post ($2.43) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This article was reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this article on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark laws. The original version of this article can be read at https://stocknewstimes.com/2017/08/17/crispr-theraptc-crsp-director-kurt-von-emster-sells-55569-shares.html.
A number of hedge funds have recently modified their holdings of CRSP. ARK Investment Management LLC acquired a new stake in shares of Crispr Theraptc during the second quarter valued at approximately $206,000. Vanguard Group Inc. acquired a new stake in shares of Crispr Theraptc during the second quarter valued at approximately $273,000. Wells Fargo & Company MN raised its stake in shares of Crispr Theraptc by 459.7% in the second quarter. Wells Fargo & Company MN now owns 7,987 shares of the company’s stock valued at $128,000 after buying an additional 6,560 shares during the last quarter. IHT Wealth Management LLC acquired a new stake in shares of Crispr Theraptc during the first quarter valued at approximately $110,000. Finally, Credit Suisse AG acquired a new stake in shares of Crispr Theraptc during the first quarter valued at approximately $1,742,000. 24.08% of the stock is currently owned by institutional investors.
CRSP has been the subject of a number of recent research reports. Chardan Capital reiterated a “buy” rating on shares of Crispr Theraptc in a research note on Monday. SunTrust Banks, Inc. initiated coverage on Crispr Theraptc in a research note on Thursday, July 13th. They set a “hold” rating and a $16.00 price objective for the company. Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of Crispr Theraptc in a research note on Tuesday, July 18th. Finally, Cann initiated coverage on Crispr Theraptc in a research note on Monday, July 17th. They set a “market perform” rating for the company. Four analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Crispr Theraptc currently has an average rating of “Buy” and a consensus price target of $21.92.
Crispr Theraptc Company Profile
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
Receive News & Ratings for Crispr Theraptc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Theraptc and related companies with MarketBeat.com's FREE daily email newsletter.
